UAE-based femtech startup Ovasave, supported by Abu Dhabi’s Hub71, has raised $1.2 million in pre-seed funding led by PlusVC, Annex Investments, and New York’s 25 Madison, alongside strategic angel investors and family offices from the UAE and Saudi Arabia. Founded in 2023 by Majd Abu Zant and Torkia Mahloul, Ovasave offers a digital-first platform combining at-home hormone testing, virtual consultations, personalized supplements, and egg freezing support. The startup also partners with corporations to integrate fertility and hormonal health into employee wellbeing programs.
The new capital will fuel Ovasave’s expansion into Saudi Arabia and the wider GCC, support scaling corporate partnerships, and enable the next phase of its mobile app with features like menstrual tracking, symptom monitoring, and AI-driven treatment protocols. The company aims to broaden services to include perimenopause and menopause care.
Ovasave’s growth aligns with the UAE’s accelerating healthcare reforms and increased focus on women’s rights, positioning the country as a regional hub for FemTech innovation. Co-founder Majd Abu Zant highlighted Abu Dhabi’s conducive ecosystem for innovation, capital access, and proximity to decision-makers as key advantages for scaling impact.
Co-founder and CEO Torkia Mahloul stressed the urgent need for accessible women’s health solutions and expressed gratitude for investor confidence enabling Ovasave to disrupt the sector with timely, personalized care. The startup also actively promotes public education and normalizes fertility conversations through awareness campaigns and partnerships with major employers like Aldar and Boston Consulting Group.
According to FemTech Analytics, the MENA FemTech market is projected to reach $3.8 billion by 2031 with a 15% CAGR, reflecting growing investor interest and regional momentum.
